Pyrimethamine was approved as a generic in the United States in February 2020.In January 2020 the FTC filed a case against Vyera "alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim". A settlement was reached in December 2021. According to AP News, the settlement "requires Vyera and Phoenixus to provide up to $40 million in relief over 10 years to consumers who allegedly were fleeced by their actions and requires them to make Daraprim available to any potential generic competitor at the cost of producing the drug." According to Law360, company executive Kevin Mulleady "agreed to a seven-year ban on working for or holding more than an 8% share in most pharmaceutical companies." Other countries
In India, over a dozen manufacturers sell pyrimethamine tablets, and multiple combinations of generic pyrimethamine are available for a price ranging from US$0.04 to US$0.10 each (3–7 rupees).In the UK, the same drug is available from GSK at a cost of US$20 (£13) for 30 tablets (about $0.66 each).In Australia, the drug is available in most pharmacies at a cost of US$9.35 (A$12.99) for 50 tablets (around US$0.18 each).In Brazil, the drug is available for R$0.07 a pill, or about US$0.02.In Canada, the drug was reportedly discontinued in 2013, but hospitals may make the drug in-house when it is needed. As of December 2015, Daraprim imported into Canada directly from GSK UK is available from an online pharmacy for US$2.20 per tablet.In Switzerland, the drug is available for US$9.45 (CHF9.05) for 30 tablets (around US$0.32 a piece).
For some patients with intense affliction, there often can be unremitting nausea, causing vomiting. The pain can also bring on hyperventilation. Blood pressure can rise due to the pain. Cause
Damage to the CNS can be caused by car accidents, limb amputations, trauma, spinal cord injury, tumors, stroke,  immune system disorders or diseases, such as multiple sclerosis, Parkinsons, Graves or Addisons disease, rheumatoid arthritis, and epilepsy. It may develop months or years after injury or damage to the CNS. Diagnosis
A diagnosis of central pain syndrome is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. Central pain syndrome is suspected in individuals who complain of pain or other abnormal sensations following injury to the central nervous system. Other conditions that cause pain may need to be excluded before a diagnosis of central pain syndrome is made. Treatment
Pain medications often provide some reduction of pain, but not complete relief of pain, for those affected by central pain syndrome. Tricyclic antidepressants such as nortriptyline or anticonvulsants such as neurontin (gabapentin) can be useful, but also provide incomplete relief. Lowering stress levels appears to reduce pain. For regular treatment some people prefer body length heating pads while others rely on warm baths. Prognosis
Central pain syndrome is not a fatal disorder, but the syndrome causes disabling chronic pain and suffering among the majority of individuals who have it. See also
Thalamic syndrome

References
Further reading
Canavero S, & Bonicalzi V (2007) Central pain syndrome.